Aradigm (NASDAQ:ARDM) issued its quarterly earnings results on Tuesday. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.10, Bloomberg Earnings reports. The firm had revenue of $1.47 million for the quarter.
Shares of Aradigm traded down $0.07, hitting $1.46, during mid-day trading on Wednesday, Marketbeat reports. The company had a trading volume of 1,100 shares, compared to its average volume of 277,886. Aradigm has a 52-week low of $1.43 and a 52-week high of $1.51. The company has a debt-to-equity ratio of -1.20, a quick ratio of 1.41 and a current ratio of 1.41. The company has a market capitalization of $22.36 million, a PE ratio of -2.04 and a beta of 0.89.
Separately, Zacks Investment Research downgraded shares of Aradigm from a “hold” rating to a “sell” rating in a report on Friday, April 13th.
Aradigm Company Profile
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium.
Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with MarketBeat.com's FREE daily email newsletter.